Ordered Items
Leflunomide Metabolite (ARAVA)

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leflunomide Metabolite (ARAVA)</td>
<td>None Detected</td>
<td>ng/mL</td>
<td>01 Detection Limit = 20</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For women under treatment with Arava (leflunomide) who desire to become pregnant, it is recommended to monitor the levels of the active leflunomide metabolite, teriflunomide (A77-1726). The teriflunomide serum concentration should be less than 20 ng/mL from two separate collections taken at least 14 days apart. If serum levels are greater than 20 ng/mL, additional cholestyramine treatments should be considered.

Steady state is reached between 7 and 8 weeks. In some studies, the serum trough teriflunomide concentrations for patients on daily regimens of 5, 10, and 24 mg of leflunomide yielded serum concentrations of 9000, 18000 and 63000 ng/mL, respectively.

Comments:

* This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
Patient Details
DOB: 11/13/1959
Age(y/m/d): 059/02/17
Gender: F
SSN: 
Patient ID: 

Specimen Details
Date collected: 01/30/2019 0000 Local
Date received: 01/30/2019
Date entered: 01/30/2019
Date reported: 01/30/2019 0000 ET

Physician Details
Ordering: 
Referring: 
ID: 
NPI: 

General Comments & Additional Information
Clinical Info: ABNORMAL REPORT

Ordered Items
Leflunomide Metabolite (ARAVA)

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leflunomide Metabolite (ARAVA) (^a)</td>
<td>435</td>
<td>ng/mL</td>
<td>01</td>
<td>Detection Limit = 20</td>
<td></td>
</tr>
</tbody>
</table>

For women under treatment with Arava (leflunomide) who desire to become pregnant, it is recommended to monitor the levels of the active leflunomide metabolite, teriflunomide (A77-1726). The teriflunomide serum concentration should be less than 20 ng/mL from two separate collections taken at least 14 days apart. If serum levels are greater than 20 ng/mL, additional cholestyramine treatments should be considered.

Steady state is reached between 7 and 8 weeks. In some studies, the serum trough teriflunomide concentrations for patients on daily regimens of 5, 10, and 24 mg of leflunomide yielded serum concentrations of 9000, 18000 and 63000 ng/mL, respectively.

Comments:
\(^a\) This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

01 BN LabCorp Burlington
1447 York Court, Burlington, NC 27215-3361
Dir: Sanjai Nagendra, MD

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762